AzurRx BioPharma, Inc. (NASDAQ: AZRX) today is providing an update on the ongoing open-label Phase IIa trial of lead ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE